drugset / Trial / NCT00030108
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
Phase 1
Completed
30 enrolled
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating young patients with relapsed or refractory solid tumors or leukemia.
Timeline
- Start
- 2001-11
- Primary completion
- 2010-03
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixabepilone | Small molecule | 3 mg/m2 | Intravenous |
| Subject | Ixabepilone | Small molecule | 4.5 mg/m2 | Intravenous |
| Subject | Ixabepilone | Small molecule | 6 mg/m2 | Intravenous |
| Subject | Ixabepilone | Small molecule | 8 mg/m2 | Intravenous |
| Subject | Ixabepilone | Small molecule | 10 mg/m2 | Intravenous |